ArticleInvestigative ophthalmology & visual science2026
Rod Pathway Dysfunction in Early-Stage Diabetic Retinopathy Assessed by ERG and Pupillometry.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Purpose: To provide insight into rod pathway dysfunction in early-stage diabetic retinopathy (DR) by measuring dark-adapted ERGs and pupillary light reflexes (PLRs) across a broad range of stimulus luminance. Methods: Seventeen diabetics with no clinically apparent DR (NDR), 17 with mild nonproliferative DR (MDR), and 15 nondiabetic controls participated. Dark-adapted, full-field ERGs and PLRs were obtained. Achromatic (-4 to 1 log cd-s-m-2) and long-wavelength (-4.0 to 2.6 log cd/m2) flashes were used for ERG and pupillometry, respectively. The b-wave amplitudes and pupil diameters were fit with Naka-Rushton functions to obtain (1) maximum b-wave amplitude (Vmax), (2) maximum PLR (Pmax), (3) b-wave sensitivity (kb), and (4) PLR sensitivity (kp). Results: ERG a-wave amplitude was reduced (0.13 log µV averaged across stimulus luminance) in DR compared with the controls, but this was not statistically significant (F = 1.41; P = 0.25). ERG Vmax did not significantly differ among groups (F = 2.20, P = 0.12), whereas kb was elevated (reduced sensitivity) for both groups (both t > 2.40; P < 0.02). Pupil Pmax was reduced in MDR (t = 2.83, P = 0.01), but not NDR (t = 0.99, P = 0.33). Pupil kb was significantly elevated in NDR and MDR (both t > 2.1; P < 0.04). Conclusions: Reduced b-wave amplitude may largely be accounted for by the reduced a-wave amplitude. By contrast, pupil sensitivity loss greatly exceeded the b-wave sensitivity loss, suggesting sites of abnormality beyond the bipolar cells contribute to pupil response deficits in diabetics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.